Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Basit Öğe Kaydı
dc.contributor.authorBaykara, Meltem
dc.contributor.authorCoskun, Ugur
dc.contributor.authorBerk, Veli
dc.contributor.authorOzkan, Metin
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorKaraca, Halit
dc.date.accessioned2024-04-24T17:28:14Z
dc.date.available2024-04-24T17:28:14Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: The aim of this retrospective study was to determine response rates, progression-free survival (PFS), overall survival (OS) and toxicity of gemcitabine and paclitaxel combinations with advanced or metastatic non-small cell lung cancer patients (NSCLC) who have progressive disease after platinum-based first-line chemotherapy. Methods: We retrospectively evaluated the file records of patients treated with gemcitabine plus paclitaxel in advanced or metastatic NSCLC cases in a second-line setting. The chemotherapy schedule was as follows: gemcitabine 1500 mg/m(2) and paclitaxel 150 mg/m(2) administered every two weeks. Results: Forty-eight patients (45 male, 3 female) were evaluated; stage IIIB/IV 6/42; PS0, 8.3%, PS1, 72.9%, PS2, 18.8%; median age, 56 years old (range 38-76). Six (12.5%) patients showed a partial response (PR), 13 (27.1%) stable disease (SD), and 27 (56.3%) progressive disease (PD). The median OS was 6.63 months (95% CI 4.0-9.2); the median PFS was 2.7 months (95% CI 1.8-3.6). Grade 3 and 4 hematologic toxicities, including neutropenia (n=4, 8.4%), and anemia (n=3, 6.3%) were encountered, but no grade 3 or 4 thrombocytopenia. One patient developed febrile neutropenia. There were no interruption for reasons of toxicity and no exitus related to therapy. Conclusion: The combination of two-weekly gemcitabine plus paclitaxel was an effective and well-tolerated second-line chemotherapy regimen for advanced or metastatic NSCLC patients previously treated with platinum-containing chemotherapy. Although the most common and dose limiting toxicities were neutropenia and neuropathy, this regimen was tolerated well by the patients.en_US
dc.identifier.doi10.7314/APJCP.2012.13.10.5119
dc.identifier.endpage5124en_US
dc.identifier.issn1513-7368
dc.identifier.issue10en_US
dc.identifier.pmid23244121
dc.identifier.scopus2-s2.0-84874002741
dc.identifier.scopusqualityQ3
dc.identifier.startpage5119en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.10.5119
dc.identifier.urihttps://hdl.handle.net/11468/20375
dc.identifier.volume13en_US
dc.identifier.wosWOS:000315302600053
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectSecond-Line Therapyen_US
dc.subjectGemcitabineen_US
dc.subjectPaclitaxelen_US
dc.titleGemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Canceren_US
dc.titleGemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu